RxDoctor Payments DataLook up a doctor →

Ammar Yousif, MD

Hematology & Oncology · Las Vegas, NVNPI 1457745531

Payments from drug & device makers

$44,552in general payments, 2019–2025

Across 989 payments — averaging $45.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$23K
  • Novartis$3K
  • Incyte Corporation$1K
  • Johnson & Johnson$1K
  • AstraZeneca$1K
  • Daiichi Sankyo Inc.$866
  • plus $13K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck40$23,211
Novartis89$3,324
Incyte Corporation43$1,239
Johnson & Johnson(2 entities)63$1,218
AstraZeneca(2 entities)55$1,112
Daiichi Sankyo Inc.75$866
Astellas Pharma US Inc35$847
Bristol Myers Squibb42$813
Amgen38$729
Pfizer42$615
E.r. Squibb & Sons, L.L.C.36$576
Sobi, Inc26$542
Eisai Inc.27$541
Beigene USA, Inc.22$488
Exelixis Inc.17$488
GSK25$472
EMD Serono, Inc.24$472
Gilead(2 entities)15$462
Takeda Pharmaceuticals U.S.A., Inc.12$361
Seagen Inc.12$339
Genentech USA, Inc.15$319
Regeneron Healthcare Solutions, Inc.14$308
Sanofi13$263
Boehringer Ingelheim10$235
Lilly USA, LLC9$227
Sanofi-aventis U.S. LLC3$223
Menarini Silicon Biosystems, Inc.3$218
Genmab U.S., Inc.9$207
Bayer10$193
Jazz Pharmaceuticals Inc.10$191
Stemline Therapeutics Inc.10$182
Puma Biotechnology, Inc.8$169
Myovant Sciences Inc.9$167
Sirtex Medical Inc2$158
AbbVie7$145
Rigel Pharmaceuticals, Inc.6$144
Array Biopharma Inc10$144
Ipsen Biopharmaceuticals, Inc8$143
Pharmacosmos Therapeutics Inc.5$123
Foundation Medicine, Inc.6$120
Dendreon Pharmaceuticals LLC5$118
Recordati_rare_diseases_inc.4$107
Karyopharm Therapeutics Inc.4$98
Beone Medicines USA, Inc.4$96
Clovis Oncology, Inc.5$96
Taiho Oncology, Inc.3$89
Sumitomo Pharma America, Inc.4$89
Mirati Therapeutics, Inc.4$88
Pharmacyclics LLC, An Abbvie Company3$78
Deciphera Pharmaceuticals Inc.3$78
EUSA Pharma (US) LLC3$72
Coherus Oncology, Inc.3$71
Springworks Therapeutics, Inc.3$70
CTI Biopharma Corp.3$67
Servier Pharmaceuticals LLC3$67
Geron Corporation2$62
Tempus AI, Inc2$59
Pharmaessentia USA Corporation2$54
Organon3$48
Kyowa Kirin, Inc.2$42

How this compares

$44,552 in reported general payments places this provider in the 55th percentile of 82 hematology & oncology providers in Nevada.

See all hematology & oncology providers in Nevada →

Medicare billing

Part B allowed, 2024
$1,556,694
Medicare patients
113
Services billed
40,368

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Las Vegas

See the full list for Nevada →

Where these figures come from

Is this you, or does something look wrong? →